Cheng Chun-Han, Hao Wen-Rui, Cheng Tzu-Hurng
Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan.
Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan.
World J Cardiol. 2024 Dec 26;16(12):781-786. doi: 10.4330/wjc.v16.i12.781.
This article addresses the substantial findings of a study on sodium-dependent glucose transporter 2 inhibitors (SGLT2is) and their effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure. The editorial explores the broader implications of the study findings for clinical practice, thus highlighting the pivotal role of SGLT2is in improving cardiac function, reducing oxidative stress, and attenuating inflammation. It emphasizes the importance of early intervention with SGLT2is in preventing the progression of diabetic cardiomyopathy; hence, these inhibitors have the potential to transform the management of asymptomatic heart failure in patients with diabetes.
本文阐述了一项关于钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）及其对2型糖尿病合并无症状心力衰竭患者心肌功能影响的研究的重要发现。这篇社论探讨了该研究结果对临床实践的更广泛影响，从而突出了SGLT2is在改善心脏功能、降低氧化应激和减轻炎症方面的关键作用。它强调了早期使用SGLT2is进行干预在预防糖尿病性心肌病进展中的重要性；因此，这些抑制剂有可能改变糖尿病患者无症状心力衰竭的管理方式。
